

FDF Product list (July 2020)

Product Family Name	Dosage Form	Dosage Strength	Development Status	Dossier Readiness	ATC Group	4B Zone Stability*
ABACAVIR SULFATE + LAMIVUDINE	Film-coated tablet	702 + 300 mg (600/300 mg)	ready	dossier registered	Antiinfectives for systemic use	not available
ABIRATERONE ACETATE	Film-coated tablet	500 mg	ongoing	Q3 2020	Antineoplastic and immunomodulating agents	available
ACETYLSALICYLIC ACID	Tablet	100 mg	ongoing	Q4 2021	Nervous system	not available
AMLODIPINE	Tablet	5mg, 10mg	ready	dossier registered	Cardiovascular system	available
AMLODIPINE BESILATE + CANDESARTAN CILEXETIL	Tablet	6.945 + 8 mg; 6.945 + 16 mg; 13.889 + 16 mg (5/8, 5/16, 10/16 mg)	ready	dossier registered	Cardiovascular system	available
AMLODIPINE BESILATE + INDAPAMIDE + PERINDOPRIL ERBUMINE	Tablet	6.934 + 1.25 + 4 mg; 13.868 + 1.25 + 4 mg; 6.934 + 2.5 + 8 mg; 13.868 + 2.5 + 8 mg (5+1.25+4; 10+1.25+4; 5+2.5+8; 10+2.5+8 mg)	ready	dossier registered	Cardiovascular system	available
AMLODIPINE BESILATE + PERINDOPRIL ERBUMINE	Tablet	6.934 + 4 mg; 13.868 + 4 mg; 6.934 + 8 mg; 13.868 + 8 mg (5/4; 10/4; 5/8; 10/8 mg)	ready	dossier registered	Cardiovascular system	available



Product Family Name	Dosage Form	Dosage Strength	Development Status	Dossier Readiness	ATC Group	4B Zone Stability*
AMLODIPINE BESILATE + VALSARTAN	Film-coated tablet	6.935 + 80 mg; 6.935 + 160 mg; 13.870 + 160 mg (5/80; 5/160; 10/160 mg)	ready	dossier registered	Cardiovascular system	available
APIXABAN	Film-coated tablet	2.5 mg, 5 mg	ongoing	Q2 2024	Blood and blood forming organs	available
APREMILAST	Film-coated tablet	10 mg, 20 mg, 30 mg	ongoing	Q1 2023	Dermatological drugs	available
ATAZANAVIR SULFATE	Capsule, hard	170.86 mg; 227.81 mg; 341.71 mg (150 mg, 200 mg, 300 mg)	ready	dossier registered	Antiinfectives for systemic use	available
ATORVASTATIN CALCIUM	Film-coated tablet	10 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg	ready	dossier registered	Cardiovascular system	available
BISOPROLOL FUMARATE	Tablet	1.25 mg; 2.5 mg; 3.75 mg; 5 mg; 7.5 mg; 10 mg	ready	dossier registered	Cardiovascular system	not available
CLOPIDOGREL	Film-coated tablet	75 mg	ongoing	Q3 2023	Blood and blood forming organs	available
DAPAGLIFLOZIN	Film-coated tablet	5 mg, 10 mg	ongoing	Q4 2024	Alimentary tract and metabolism	not available
DEFERASIROX	Film-coated tablet	125 mg, 250 mg, 500 mg	ready	dossier registered	Various ATC structures	not available
DULOXETINE HYDROCHLORIDE	Capsule, gastro-resistant, hard	22.45 mg; 33.68 mg; 44.9 mg; 67.35 mg (20, 30, 40, 60 mg)	ready	dossier registered	Nervous system	available
ETORICOXIB	Film-coated tablet	30 mg, 60 mg, 90 mg, 120 mg	ready	dossier registered	Musculoskeletal system	not available

Product Family Name	Dosage Form	Dosage Strength	Development Status	Dossier Readiness	ATC Group	4B Zone Stability*
HYDROCHLOROTHIAZIDE + LOSARTAN POTASSIUM	Film-coated tablet	12.5 + 50 mg; 12.5 + 100 mg; 25 + 100 mg	ready	dossier registered	Cardiovascular system	not available
HYDROCHLOROTHIAZIDE + TELMISARTAN	Tablet	12.5 + 40 mg; 12.5 + 80 mg; 25 + 80 mg	ready	dossier registered	Cardiovascular system	available
IBANDRONATE SODIUM MONOHYDRATE	Film-coated tablet	168.75 mg (150 mg)	ready	dossier registered	Musculoskeletal system	available
IBUPROFEN	Film-coated tablet	200 mg, 400 mg, 600 mg, 800 mg	ready	dossier registered	Musculoskeletal system	not available
ILOPROST	Nebuliser solution	0.01 mg/ml	ready	dossier registered	Blood and blood forming organs	not available
IVABRADINE HYDROCHLORIDE	Film-coated tablet	5.390 mg; 8.085 mg (5 mg; 7.5 mg)	ready	dossier registered	Cardiovascular system	available
LACOSAMIDE	Film-coated tablet	50 mg, 100 mg, 150 mg, 200 mg	ready	dossier registered	Nervous system	available
LEVETIRACETAM	Film-coated tablet	250 mg, 500 mg, 750 mg, 1000 mg	ready	dossier registered	Nervous system	available
LINAGLIPTIN	Film-coated tablet	5 mg	ongoing	Q3 2020	Alimentary tract and metabolism	available
LINAGLIPTIN + METFORMIN	Tablet	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg	ongoing	Q2 2024	Alimentary tract and metabolism	not available
METAMIZOLE NA	Tablet	500mg	ongoing	Q4 2020	Nervous system	not available

Product Family Name	Dosage Form	Dosage Strength	Development Status	Dossier Readiness	ATC Group	4B Zone Stability*
METAMIZOLE NA	Injection	500 mg/ml (2 ml)	ongoing	Q4 2021	Nervous system	not available
METFORMIN + SITAGLIPTIN	Film-coated tablet	1000 mg/50 mg, 850 mg/50 mg	ongoing	Q2 2022	Alimentary tract and metabolisma	available
METFORMIN HYDROCHLORIDE	Film-coated tablet	500 mg, 850 mg, 1000mg	ready	dossier registered	Alimentary tract and metabolisma	available
NILOTINIB	Capsule	150 mg, 200 mg; (50 mg pending)	ongoing	Q2 2021	Antineoplastic and immunomodulating agents	not available
NOREPINEPHRINE	Injection	1 mg/ml	ongoing	Q3 2021	various	not available
PARACETAMOL	Tablet	500mg, 1000mg	ongoing	Q1 2021	Nervous system	not available
PARACETAMOL + TRAMADOL	Tablet	325 mg + 37.5 mg	ongoing	Q4 2022	Nervous system	not available
PERINDOPRIL	Film-coated tablet	2.5 mg, 5 mg, 10 mg	ongoing	Q4 2020	Cardiovascular system	not available
PRASUGREL HYDROBROMIDE	Film-coated tablet	6.070 mg; 12.140 mg (5 mg, 10 mg)	ready	dossier registered	Blood and blood forming organs	available
PRASUGREL HYDROCHLORIDE	Film-coated tablet	5,490 mg; 10,980 mg (5 mg, 10 mg)	ready	dossier registered	Blood and blood forming organs	available
RAMIPRIL	Tablet	1.25 mg, 2.5 mg, 5 mg, 10 mg	ongoing	Q3 2022	Cardiovascular system	not available
RIVAROXABAN	Film-coated tablet	2.5 mg; 10 mg, 15 mg, 20 mg	ongoing	Q2 2021	Blood and blood forming organs	available
RIVAROXABAN	Capsule, hard	2.5 mg; 10 mg, 15 mg, 20 mg	ongoing	Q2 2021	Blood and blood forming organs	available

Product Family Name	Dosage Form	Dosage Strength	Development Status	Dossier Readiness	ATC Group	4B Zone Stability*
ROSUVASTATIN CALCIUM	Film-coated tablet	5 mg; 10 mg, 20 mg, 40 mg	ready	dossier registered	Cardiovascular system	available
SERTRALINE	Tablet	50 mg, 100 mg	ongoing	Q4 2021	Nervous system	not available
SOLIFENACIN SUCCINATE	Film-coated tablet	5 mg, 10 mg	ready	dossier registered	Genitourinary system and reproductive hormones	available
TAMSULOSIN HYDROCHLORIDE	Modified-release capsule, hard	0.4 mg	ready	dossier registered	Genitourinary system and reproductive hormones	available
TICAGRELOR	Film-coated tablet	60 mg, 90 mg	ongoing	Q2 2022	Blood and blood forming organs	not available
VARDENAFIL HYDROCHLORIDE TRIHYDRATE	Film-coated tablet	5.926 mg; 11.852 mg; 23.704 mg (5 mg, 10 mg, 20 mg)	ready	dossier registered	Genitourinary system and reproductive hormones	available
VILDAGLIPTIN	Tablet	50 mg	ready	dossier registered	Alimentary tract and metabolism	available

*4B Zone stability can be fulfilled upon request if not available at the moment

DISCLAIMER:

Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.



Zent2U@zentiva.com



+420 267243231.



Zentiva Group a.s.
U Kabelovny 529/16
102 00 Prague 10
Czech Republic



www.Zent2U.com